22 Jul 2019
Dr. James Esinhart

Dr. James Esinhart is an experienced leader in the clinical research industry with over 30 years working in biopharmaceutical companies, academia, and global clinical research organizations.

Most recently, Dr. Esinhart joined Chiltern International in 2006 and became CEO in 2012. Under his leadership, Chiltern was firmly established as a leading global mid-market CRO through the expansion of the company’s international footprint, multiple acquisitions and strategic investment in processes, people and technology. From 2006 to 2017 Chiltern’s growth was more than 11x, with revenue growing to over $550m and the global workforce to over 4,500. His successful tenure culminated in the sale of Chiltern to Covance, a division of the US-listed healthcare company Laboratory Corporation of America Holdings (LabCorp) in late 2017 for $1.2bn.

Dr. Esinhart has previously held several leadership positions in clinical research, including Vice President of Medical Data Sciences at Charles River and Inveresk. Prior to this time, he was co-founder and Senior Vice President of Biometrics at PharmaResearch Corporation. He was Assistant Professor at East Carolina University School of Medicine and also served on the university’s internal review board (IRB) for all research involving human subjects. In addition, he worked in clinical biostatistics product development roles at GlaxoSmithKline and Wyeth.

Dr Esinhart holds a PhD in Biostatistics from Virginia Commonwealth University School of Medicine in Richmond, Virginia, and a BS in Statistics from Radford University.

Dr Esinhart is a member of Ergomed’s Remuneration Committee.